Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002909
Recruitment Status : Completed
First Posted : August 11, 2004
Last Update Posted : February 5, 2013
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2000
  Study Completion Date : No date given
Publications of Results:
Carducci M, Bowling MK, Eisenberger M, et al.: Phenylbytyrate (PB) for refractory solid tumors: Phase I evaluation of continuous oral PB exposure. [Abstract] Proc Am Assoc Cancer Res 39: A507, 1998.